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B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk
following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection against severe infection but relatively little is
known regarding the profile of the antibody response following first or second vaccination. We studied spike-specific antibody
responses following first and/or second Covid-19 vaccination in 299 patients with CLL compared with healthy donors. 286 patients
underwent extended interval (10–12 week) vaccination. 154 patients received the BNT162b2 mRNA vaccine and 145 patients
received ChAdOx1. Blood samples were taken either by venepuncture or as dried blood spots on filter paper. Spike-specific
antibody responses were detectable in 34% of patients with CLL after one vaccine (n= 267) compared to 94% in healthy donors
with antibody titres 104-fold lower in the patient group. Antibody responses increased to 75% after second vaccine (n= 55),
compared to 100% in healthy donors, although titres remained lower. Multivariate analysis showed that current treatment with BTK
inhibitors or IgA deficiency were independently associated with failure to generate an antibody response after the second vaccine.
This work supports the need for optimisation of vaccination strategy in patients with CLL including the potential utility of booster
vaccines.
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INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is associated with profound
immune dysregulation that progresses over the disease course.
The underlying aetiology is multifactorial, with hypogammaglo-
bulinaemia, impaired cellular immunity and therapy-related
immunosuppression commonly observed [1]. These perturbations
in immunity predispose patients to an increased risk of infection
and infection-related mortality remains a common cause of death
[2]. Vaccination against common infectious agents is of para-
mount importance in supportive care but vaccine-induced
immune responses and associated clinical efficacy are often
reduced in this patient group.
SARS-CoV-2 is a novel coronavirus and has led to a global
pandemic with over 3.2 million deaths to date. Several studies
have shown increased rates of morbidity and mortality after SARS-
CoV-2 infection in patients with CLL and this is exacerbated by the
age of many patients with this condition [3–5].
Novel vaccines against Covid-19 have shown remarkable
efficacy and are likely to play a major role in control of the
current pandemic [6]. BNT162b2 and ChAdOx1 utilise nucleoside-
modified RNA or adenovirus-based platforms, respectively, and
incorporate the SARS-CoV-2 spike protein as vaccine immunogen.
Both vaccines are given as two doses with the BNT162b2 vaccine
approved for a 3-week interval whilst clinical responses after
ChAdOx1 are improved with a longer period between prime and
boost [7]. However, several countries, including the UK, have
elected to adopt an ‘extended interval’ vaccination regimen of
between 10–12 weeks between BNT162b2 doses in order to
maximise population coverage after a single vaccine.
Covid-19 vaccines offer the potential to provide patients with CLL
with substantial clinical protection from SARS-CoV-2 infection but
there is concern regarding the efficacy of vaccine responses in this
group. Studies over many years have shown immune responses to
vaccination are impaired in patients with B-CLL [8–10]. This is seen
most particularly in the response to novel immunogens [8, 9].
Attenuated vaccine-induced immunity is seen across many stages of
the disease course but immune function deteriorates most
particularly in heavily treated patients. Vaccine responses are also
suppressed in patients who are undergoing treatment with BTK
inhibitors [8, 11]. There is relatively little information to date
regarding the efficacy of Covid-19 vaccination in patients with CLL.
Examination of 44 patients following 2 doses of mRNA vaccines
recently reported a response rate of 52% [12]. Similarly, in a larger
cohort of patients who had received the second BNT162b2 mRNA
vaccine following a standard 3-week interval between doses,
antibody responses were detected in 40%, with higher rates in
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patients with clinical remission after treatment, compared with a
response rate of only 16% for patients on current treatment [13]. No
current data exists studying ChAdOx1 in patients with CLL or for
those on extended interval schedules.
Here we present an interim assessment of spike-specific
antibody response in patients with CLL following BNT162b2 or
ChAdOx1 vaccination. Due to usage of an ‘extended interval’
vaccine protocol within the UK for most patients to date, antibody
responses have been assessed after single vaccination, with a
smaller proportion assessed following the second dose. We show
that immune responses are impaired in most patients and that IgA
deficiency and current therapy with BTKi are independent risk
factors for poor response.
METHODS
Patients with a diagnosis of CLL or small lymphocytic leukaemia (SLL) were
recruited to the study. The work was performed under the CIA UPH IRAS
approval (REC 20\NW\0240) and conducted according to the Declaration of
Helsinki and good clinical practice. Informed consent was obtained in
person or by remote consultation. Dates and subtype of SARS-CoV-2
vaccination were obtained together with self-reported information on
disease stage and date of CLL diagnosis, CLL treatment and infection
history. Infection history was considered ‘positive’ in cases of 2 or more
serious or 3 or more respiratory infections in a 1-year period. Participants
were asked about personal shielding and previous symptoms compatible
with SARS-CoV-2 infection. Participant demographics can be found in
Table 1.
Samples were obtained following first or second vaccination. Local
participants undertook a phlebotomy sample whilst those more distant
donated a dried blood spot sample (DBS) from capillary blood after a finger
prick (Fig. 1). A total of 93 healthy donor controls were recruited from local
primary care networks.
Roche Elecsys® electrochemiluminescence immunoassay
(ECLIA)
Serum was stored at −20 °C and defrosted prior to antibody analysis. IgG/
A/M antibodies specific to SARS-CoV-2 were detected using electrochemi-
luminescence assays on the automated Roche cobas e801 analysers based
Table 1. Details of patient cohort.
Total cohort DBS result Serum result
First vaccine Second vaccine First vaccine Second vaccine
Number of patients 299 267 55 86 12
Age Median (years) 69 69 70 70 82.5
IQR 63–74 63–74 65–75 65–76 80–85
Range 43–96 43–96 48–87 49–96 52–87
Sex Men 159 (53%) 143 (54%) 27 (49%) 47 (55%) 7 (58%)
Women 140 (47%) 124 (46%) 28 (51%) 39 (45%) 5 (42%)
Vaccine received Pfizer 154 (52%) 135 (51%) 38 (69%) 39 (45%) 12 (100%)
AstraZeneca 145 (49%) 132 (49%) 17 (31%) 47 (55%) 0
Time from vaccine to result Median (days) 43 18 47 39
IQR 36 to 52 16 to 27 39 to 55 35 to 53
Range 3 to 85 8 to 56 24 to 80 29 to 56
Time since diagnosis Median (months) 79 81 75 87 220.5
IQR 39–142 39–139 35–176 46–156 143–245
Range 3–411 3–345 5–411 7–279 76–411
Stage A 264 (88%) 233 (87%) 53 (96%) 78 (91%) 11 (92%)
B 15 (5.0%) 14 (5.2%) 2 (3.6%) 1 (1.2%) 1 (8.3%)
C 20 (6.7%) 20 (7.5%) 0 7 (8.1%) 0
Previous treatment W&W 181 (61%) 157 (59%) 40 (73%) 55 (64%) 9 (75%)
1 line 77 (26%) 73 (27%) 9 (16%) 23 (27%) 2 (17%)
2 lines 28 (9.4%) 25 (9.4%) 4 (7.3%) 7 (8.1%) 1 (8.3%)
3+ lines 13 (4.3%) 12 (4.5%) 2 (3.6%) 1 (1.2%) 0
On BTKi 60 (20%) 56 (21%) 8 (15%) 18 (21%) 0
On venetoclax 6 (2.0%) 6 (2.2%) 0 1 (1.2%) 0
Previous chemotherapy 71 (24%) 65 (24%) 8 (15%) 16 (19%) 2 (17%)
Previous anti-CD20 80 (27%) 75 (28%) 7 (13%) 18 (21%) 2 (17%)
Treatment planned 8 (2.7%) 6 (2.2%) 2 (3.6%) 1 (1.2%) 0
History of infections Frequent infections 76 (25%) 67 (25%) 18 (33%) 23 (27%) 3 (25%)
Hospitalisations 60 (20%) 53 (20%) 10 (18%) 14 (16%) 2 (17%)
Prophylactic antibiotics 55 (18%) 53 (20%) 3 (5.5%) 20 (23%) 0
IVIG 17 (5.7%) 17 (6.4%) 0 3 (3.5%) 0
Immunoglobulin deficiency Number 117 85 54 62 12
IgG (<6 g/L) 43 (37%) 34 (40%) 19 (35%) 24 (39%) 2 (17%)
IgA (<0.8 g/L) 34 (29%) 27 (32%) 17 (32%) 17 (27%) 4 (33%)
IgM (<0.5 g/L) 56 (48%) 45 (53%) 16 (30%) 40 (65%) 5 (42%)
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at Public Health England (PHE) Porton. Calibration and quality control were
performed as recommended by the manufacturer. Anti-nucleocapsid
protein (NP) antibodies were detected using the qualitative Roche Elecsys®
AntiSARS-CoV-2 ECLIA (COV2, Product code: 09203079190), whilst anti-
spike (S) antibodies were detected using the quantitative Roche Elecsys®
Anti-SARS-CoV-2 S ECLIA (COV2 S, Product code 09289275190). Anti-
nucleocapsid results are expressed as a cut-off index (COI) value, with a COI
value of ≥1.0 considered positive for anti-nucleocapsid antibodies. Anti-
spike results are expressed as units per ml (U/ml), with samples with a
result of ≥0.8 U/ml considered positive for anti-spike antibodies within the
fully quantitative range of the assay: 0.4–2500 U/ml. Samples >2500 U/ml
were diluted further (1:10, 1:100, and 1:1000) to within the
quantitative range.
Dried blood spot ELISA analysis
Dried blood spot analysis was carried out by Clinical Immunology Service
(University of Birmingham). Capillary blood samples were collected on DBS
cards (Ahlstrom Munksjo) from participants remotely and stored at room
temperature. Samples were eluted in 250 microlitres of 0.05% phosphate-
buffered saline-Tween 20 (PBS, Oxoid Tween-20, Sigma-Aldrich) per blood
spot and incubated overnight (12–16 h) before centrifugation (10,600 x g
for 10 min). The DBS eluate was then applied to a pre-coated 96-well ELISA
plate (The Binding Site (TBS), Birmingham, UK) containing stabilised
trimeric SARS-CoV-2 spike glycoprotein and detecting IgG, IgA and IgM
antibody isotypes [14]. The performance characteristics for this assay were
assessed in 162 non-hospitalised mild to moderate disease PCR-positive
individuals and 707 presumed COVID-19 negative samples from pre-2019.
Sensitivity was 96.3% (92.1−98.6) and specificity 99.3% (98.4−99.8). The
ELISA output result was reported as a ratio relative to a monoclonal spike-
specific calibration antibody standard and multiplied by the previously
determined cut-off co-efficient to maintain batch-to-batch consistency,
defined as 1.31. A positive result was classed as a ratio of 1 or more.
Serum immunoglobulin measurement
Quantification of IgG, IgA and IgM was evaluated using the COBAS 6000
(Roche) at the University of Birmingham Clinical Immunology Service. For
analysis of DBS eluates, levels were multiplied by 10.7 to account for
dilution factor and following validation of paired DBS and healthy serum
samples.
Statistical analysis
Data were tested for normality using Kolmogorov–Smirnov analysis. For
comparative analysis of antibody titres between healthy donors and
patients with CLL, Mann–Whitney U-tests were performed. Spearman rank
correlation was used for comparing assay platforms and for correlating
total serum Ig and time since diagnosis against anti-S responses. For
comparison of anti-S response by CLL treatment groups, Kruskal–Wallis
was performed with post-hoc Dunn’s analysis and paired 1st and 2nd
vaccine responses, Wilcoxon’s matched-pairs signed rank test was used.
Binary logistic regression of clinical variables was performed to test for
associations with positive antibody response after the second vaccine. All
analysis was performed using Graphpad prism v9.1.0 for Mac (San Diego,
California USA) aside from logistic regression for which SPSS Statistics
v27.0 for Windows (Armonk, NY: IBM Corp.).
RESULTS
Patient characteristics
A total of 299 patients were enrolled in the study together with 93
age-matched healthy donors. The median age of the patient
group was 69 years (IQR 63-74) and 159 of the CLL patients (53%)
were male. A total of 154 patients had received the Pfizer-
BioNTech mRNA vaccine (BNT162b2) whilst 145 received the
AstraZeneca/Oxford ChAdOx1 adenovirus vaccine.
286 patients (96%) were vaccinated with an ‘extended interval’
regimen of 10–12 weeks between the first and second vaccine. In this
group blood samples were taken after the first vaccine in most cases
in order to assess the immune response to single vaccine delivery.
Thirteen patients (4%) were vaccinated according to the ‘standard
interval’ for the mRNA vaccine of a 3-week time period between first
and second dose. In this group samples were taken only after the
second vaccine. Matched samples after first and second vaccine were
available in 27 cases. The median time to sample collection following
the first vaccination was 43 days (IQR: 36–52 days; n= 267) whilst the
median time to sample collection following second vaccination was
18 days (IQR: 14–28; n= 55) (Fig. 1).
One hundred and eighty one patients (61%) were at stage A and
were untreated with ‘watch and wait’ monitoring. One hundred and
eighteen (39%) had received treatment for CLL, of which 66 (22%)
were actively being treated. The type and number of lines of therapy
is shown in Table 1. Seventy-six patients (25%) reported a clinical
history of frequent infections whilst 60 (20%) also reported previous
hospital admission for infection. Fifty-five patients were on
prophylactic antibiotics (18%) and 17 were on immunoglobulin
replacement therapy (6%). The median time from diagnosis to
sample collection was 79 months (IQR 39–142 months).
Antibody responses following first vaccination are markedly
reduced in patients with CLL
Antibody responses in patients undergoing extended-interval
vaccination were determined at 5–6 weeks after the initial vaccine.
Fig. 1 Infographic of study design and collection. Samples were collected from patients who had undergone dual vaccination with either an
‘extended interval’ (n= 286) or ‘standard interval’ regimen (n= 13). Antibody levels in serum samples obtained by phlebotomy or in eluates
from dried blood spot samples were assessed at the indicated timepoints.
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Analysis was performed on venepuncture serum samples (S1) in
86 patients and a simultaneous dried blood spot sample (DBS1)
was also taken at the same time in 82 subjects. An additional 185
patients provided a DBS1 sample following the first vaccine such
that a total of 267 samples were available for analysis.
Twenty-nine of the 86 serum S1 samples (34%) gave a positive
anti-spike antibody response using the Roche platform. This
overall response rate was 2.8-fold lower than that of age-matched
healthy donors where 94% were found to have detectable
antibodies. Median antibody titres were also markedly reduced
and were 104-fold lower in patients compared to healthy donors
(0.4 vs 41.6 U/ml respectively; p < 0.0001) (Fig. 2A, C). The median
titre amongst patients with a positive result was 3.96 (10.5-fold
lower than healthy donors) whilst the median titre response of
those who responded to the first vaccine but had no evidence of
previous infection was 2.49 (16-fold lower than healthy donors).
Several studies have now shown that people who have had a
previous natural SARS-CoV-2 infection exhibit particularly strong
immune responses following Covid-19 vaccination. Previous
infection can be determined by the presence of nucleocapsid-
specific antibodies and these were detected in 5 donors with CLL.
Within this group, median antibody titres within S1 samples were
boosted by a remarkable 21,450-fold to reach a median value of
8580 U/ml (naturally infected median 8580 U/ml vs no previous
infection 0.4 U/ml; p < 0.0001). Of note these values are
comparable to the levels of 10,700 U/ml in samples from healthy
donors with previous infection after one vaccine (p > 0.999).
Given the clinical heterogeneity amongst patients with CLL we
next assessed antibody responses in relation to clinical status and
management. Patients were divided into 5 groups: ‘watch and
wait’; previously completed chemo-immunotherapy (median
68 months (IQR 35-115) since last treatment); current treatment
with BTK inhibitor; current treatment with venetoclax; and ‘plans
to start treatment imminently’. Analysis of serum samples showed
that responses were low in all five groups and, although numbers
within the subgroups were small, patient responses were
particularly suppressed amongst those on current therapy or
those who were due to start therapy in the near future (Fig. 2B).
Following analysis of the serum samples we went on to
determine the spike-specific antibody response from dried blood
spot samples (DBS) using a spike-specific ELISA (The Binding Site
(TBS)). These DBS1 samples were available in 267 patients and
compared to values from 93 age-matched healthy donors
following single vaccination. Analysis of paired samples showed
a strong correlation between the spike-specific antibody response
detected by serum and DBS within the patient group (r= 0.65; p <
0.0001) (Supplementary Fig. 1A) and confirms previous work
within healthy donors [15].
Antibody responses were detectable in 63 of the 267 DBS1
patient samples (24%) which compares to the value of 34% from
the serum analysis. Positive responses were detectable in 71% of
the control group and as such were somewhat lower than
responses obtained from analysis of serum samples (Fig. 2D, F).
The magnitude of antibody response from DBS eluates was also
lower within the patient group compared to controls (median
ratio to calibrator of 0.5 vs 1; p < 0.0001) (Fig. 2D). Amongst the
24% of patients where a positive antibody response was seen, a
similar median ratio was observed in patients with CLL and
healthy donors (CLL: 1.76 vs HD 1.71). Analysis of DBS1 eluate
samples showed low responses across all patient groups.
Comparison between subgroups showed that patients on BTKi
therapy were less likely to develop a positive antibody response
compared to those on watch and wait (p= 0.0056) (Fig. 2E). No
difference was observed between patients who received the
BNT162b2 and ChAdOx1 vaccines (Supplementary Fig. 1B).
Antibody responses improve after second vaccination but
remain low compared to age-matched controls
We next went on to assess antibody responses at 2–3 weeks
following the second vaccine. At the current time, due to
widespread adoption of the ‘extended interval’ vaccine regimen
in the UK, samples are available on only 12 serum and 55 DBS
samples (termed S2 and DBS2 samples, respectively). Spike-
specific antibody responses were identified in 9 of the 12 serum
samples from the patient group (75%) compared to a 100%
response rate in healthy age-matched controls (n= 59) (Fig. 3C).
The titre of this anti-spike antibody response was 74-fold lower in
patients with CLL compared to healthy age-matched donors
without previous infection (n= 59) (53 U/ml vs 3900 U/ml; p <
0.0001) (Fig. 3A, C). Amongst the 75% of patients with a positive
Fig. 2 Antibody responses in patients with CLL following first Covid-19 vaccine. A Antibody responses to SARS-COV19 Spike following first
vaccine in sera from healthy donors (HD) and patients with CLL, as measured by Roche assay. Red indicates those previously exposed (PE) to
SARS-CoV-2 (median HD 41.6 vs CLL 0.4 (104 fold change)); cut off for positivity at 0.8 shown by dotted line. B Antibody responses to SARS-
CoV-2 Spike in patients with CLL following first vaccine, by management stage, as measured by Roche (Total patients; Watch and Wait (W+W);
Previous Chemo-immunotherapy but not on active therapy (pCI); Bruton Tyrosine Kinase therapy (BTKi); Venetoclax therapy (Ven); Treatment
planned (TP). C Bar chart to show the percentage response after first vaccine in healthy donors and CLL measured by Roche. D Antibody
responses to SARS-CoV-2 Spike from DBS in healthy donors (HD) and patients with CLL, as measured by The Binding Site (TBS) assay using
DBS eluates (median 1 vs 0.5; p < 0.0001; (cut off positivity shown at 1). E Antibody responses to SARS-CoV-2 Spike in patients with CLL
following first vaccine, by management stage, as measured by TBS using DBS eluates (Kruskal–Wallis p= 0.0054; post hoc Dunn’s analysis p <
0.0056W+W vs BTKi). F Bar chart to show the percentage response after first vaccine in HD and CLL measured by TBS using DBS eluates.
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antibody response, the median response was 102 U/ml. Eight of
these patients were on ‘watch and wait’management (Fig. 3B) and
no patients in the group had serological evidence of previous
natural SARS-CoV-2 infection.
Spike-specific antibody responses were then assessed in the 55
DBS2 samples. Antibodies were detectable in 71% of patients (39/55)
compared to 97% (36/37) of samples from healthy donors
(n= 37) (Fig. 3F). Antibody levels, as assessed by the DBS2 ratio,
were also significantly lower amongst the 55 patients (2.9 vs 4.5
healthy donors; (p= 0.0004; Fig. 3D), whilst those with a detectable
antibody response had a median ratio of 3.86. Analysis of responses
in relation to clinical status showed lower antibody levels in patients
on BTKi therapy (Figs. 3E and 4B).
Paired samples after the first and second vaccine were available
for 27 donors and revealed similar fold-increment in antibody levels
between timepoints within both the patient group and 19 age-
matched healthy donors (Fig. 4A). As such these data indicate that
patients with CLL get an equivalent proportionate antibody response
after the second vaccine although values both before and after this
vaccine remain lower than those in the control group.
Total serum immunoglobulin levels were also determined on
DBS2 samples for subsequent assessment of their relationship to
spike-specific antibody response. Seventeen of the 55 patients
(35%) were found to be IgG deficient, 19 (32%) were IgA deficient
and 16 (30%) were IgM deficient (Fig. 4C). A combined deficiency
of IgG and IgA was present in 10 (18%) patients (Fig. 4D).
Determinants of response to second vaccine
The relative importance of individual clinical and laboratory variables
on the probability of developing a positive spike-specific antibody
response after second vaccination were then assessed in univariate
analysis against values obtained from DBS2 samples (Table 2).
The age of the patient and the duration of time since diagnosis
were not associated with the probability of generating a positive
antibody response (Supplementary Fig. 2). Antibody response rates
were lower in patients who reported a history of severe infection but
this did not reach statistical significance. Serum concentrations of
IgG, IgA or IgM all showed positive correlations with antibody
response but this remained significant only for IgA in multivariate
analysis (IgA: OR 9.1; 2–42, p= 0.005). Current therapy with BTK
inhibitors was associated with markedly reduced likelihood of a
positive response to vaccination and remained significant in
multivariate analysis (OR: 0.05; 95% CI: 0.004–0.58, p= 0.016).
DISCUSSION
SARS-CoV-2 vaccines have proven highly effective in protection
against severe Covid-19 but there remains considerable concern
about their efficacy in patients with immune suppression [16].
Here we show that immune responses elicited after the first and
second vaccine are substantially reduced in patients with chronic
lymphocytic leukaemia. These findings raise a number of
questions in relation to optimisation of vaccine protection in this
vulnerable cohort.
The median age of our cohort was 69 years and as such it would
be expected that immune senescence will play a role in vaccine
response [17]. Importantly we were able to compare the patient
responses with a large age-matched control group. Antibody
responses within the patient group after one vaccination were low
and detectable in only 34% compared to 94% of age-matched
controls. The antibody titre was also over 100-fold lower at this
time. These results are comparable with the 18% response rate in
a haematological cancer cohort that included 11 CLL patients [16].
Interestingly, 5 of the 86 donors for which serological samples
were available showed the presence of nucleocapsid-specific
antibodies indicating previous natural infection and in this group
the antibody response after first vaccine was remarkably high and
directly comparable to those seen in previously infected healthy
donors after vaccination. Indeed, antibody levels were markedly
higher than those seen in previously uninfected patients after two
Covid-19 vaccines. As such, immune memory after natural infection
appears able to overcome the impaired antibody response to the
Fig. 3 Antibody responses in patients with CLL following second Covid-19 vaccine. A Antibody responses to SARS-CoV-2 Spike following
second vaccine in sera from healthy donors (HD) and patients with CLL, as measured by Roche assay. No donors had evidence of previous
exposure (cut off for positivity at 0.8 indicated by dotted line). B Dot plot of antibody responses to SARS-CoV-2 Spike in patient with CLL
following second vaccine, by management stage is shown, (W+W watch and wait; PCi previous chemo-immunotherapy but not on active
therapy) as measured by Roche. C Bar chart to show the percentage response after second vaccine in HD and CLL measured by Roche.
D Antibody responses to SARS-CoV-2 spike following second vaccine in healthy donors (HD) and patients with CLL, as measured by TBS assay
(cut off for positivity indicated by the dotted line at a ratio of 1). E Antibody responses to SARS-CoV-2 Spike in patient with CLL following
second vaccine, by management stage, DBS testing and analysed by TBS assay (Kruskal–Wallis p < 0.0045 and Dunn’s analysis for BTKi therapy
and W+W p= 0.03). Watch and Wait (W+W); Previous Chemo-immunotherapy but not on active therapy (pCI); Bruton Tyrosine Kinase therapy
(BTKi); Treatment planned (TP). F Bar chart to show the percentage response after second vaccine in HD and CLL measured by TBS assay using
DBS eluates.
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initial vaccine in the patient group. Similar findings in relation to the
‘vaccine-priming’ effect of previous natural infection have previously
been reported [15, 18, 19]. Of interest, only 2 of these 5 patients
reported symptoms compatible with SARS-CoV-2 infection over the
last 12 months suggesting that asymptomatic infection occurs
amongst patients with CLL and that mortality rates may have
therefore been overestimated [3, 5]. One limitation to this finding
may be that some patients with CLL who had previous natural
infection may lack a nucleocapsid-specific antibody response in the
convalescent serum due to antibody waning, secondary immuno-
deficiency or hypogammaglobulinaemia.
Encouragingly, antibody responses increased after the second
vaccine and were positive in 75% of serum samples and 71% of
DBS eluates at this time point. These values are somewhat higher
than the response rate of 40% in a recent study of 167 patients
after the second BNT162b2 vaccine [13]. Further assessment of
donors within our study at this time point is ongoing as more
samples are collected. Of note, most patients in this study were
studied after extended interval vaccination and this may
potentially serve to boost antibody responses following the
second vaccine [7]. Our study has found no difference in antibody
levels following the BNT162b2 or ChAdOx1 vaccines to date.
Of interest, spike-specific antibody levels within patients after
second vaccination were broadly comparable to those seen in the
control group after a single vaccine which is noteworthy given the
clinical protection demonstrated following a single vaccine within
the general population [20].
We were further interested to see how vaccine responses varied in
relation to clinical and laboratory features of individual patients.
Patient age, or time since original diagnosis, did not impact
significantly on vaccine response. In contrast the serum level of
immunoglobulin was a notable determinant, with higher levels of all
three isotypes associated with improved antibody response rate in
univariate analysis. IgA deficiency emerged as the most significant
predictor of poor vaccine response and normal levels were
associated with a 10-fold increase in the probability of a positive
response after second vaccination. IgA is the first of the
immunoglobulin classes to diminish in patients with CLL [21] and
this is reflected in this cohort where 32% of participants were
deficient in IgA. IgA levels at diagnosis have also been shown to
predict infection risk [22] and IgA deficiency has been associated
with poor responses to pneumococcal polysaccharide vaccines [23].
Herishanu et al. also found that having normal immunoglobulins
predicted better response rates to the BNT162b2 vaccination [13].
Bruton tyrosine kinase inhibitor therapy was a strong and
independent predictor of negative antibody response after the
second vaccine. BTKi therapy has transformed the management of
patients with CLL over the past decade but its impact on vaccine
response has been previously reported and is unsurprising given
the pivotal role of BTK in B-cell activation [8, 11]. It would appear
advisable that patients who are being considered for BTKi therapy
should receive their Covid-19 vaccination prior to therapy where
possible. However, we also observed suboptimal vaccine
responses in untreated patients who were planning to start
therapy in the near future and this is likely to reflect the
immunosuppressive impact of active disease.
Fig. 4 Determinants of Covid-19 vaccine response in patients with CLL. A Paired analysis of antibody responses to SARS-CoV-2 Spike in
healthy donors (HD) and patients with CLL after first and second vaccine (Analysis by TBS ELISA, HD median post 1st and 2nd vaccine 1.0 & 5.8
vs CLL median 0.5 & 3.0, respectively) with cut off for positivity shown by dotted line ratio= 1). B Dot plot showing antibody responses to
second vaccine in patients with CLL taking a Bruton Tyrosine Kinase inhibitor (BTKi) and those not on BTKi (median BTKi 0.6 vs No BTKi 3.2 p=
0.0002) as measured by TBS assay. C Correlation between antibody response to SARS-CoV-2 following second vaccine and serum
immunoglobulin. Antibody levels were measured by TBS ELISA and shown against total serum IgA (p= 0.0004; r= 0.43, IgA deficiency (0.8 g/
L) is highlighted in blue); total serum IgG (p= 0.02; r= 0.29, IgG deficiency (6 g/L) highlighted in blue) and total serum IgM (p= 0.01, r= 0.334,
IgM deficiency (<0.5 g/L) highlighted in blue). D Infographic of patients with CLL according to the presence or absence of antibody response
following double vaccination according to disease characteristics (n= 55).
Table 2. Univariate analysis of determinants of positive antibody
response after second vaccine.
Variable Odds ratio (95% CI) P value
Age (increasing) 0.99. (0.93 to 1.05) 0.73
Duration of CLL (increasing) 1.0. (0.99 to 1.002) 0.15
lgA (normal) 10.7 (2.7 to 43) 0.001
lgG (normal) 2.5. (0.73 to 8.8) 0.14
lgM (normal) 2.9 (0.83 to 10.3) 0.095
BTKI treatment (Yes) 0.034 (0.004 to 0.31) 0.003
Infection history (Yes) 0.35 (0.1 to 1.2) 0.086
H. Parry et al.
6
Blood Cancer Journal          (2021) 11:136 
In contrast, positive antibody responses were observed in 83% of
patients who were on ‘watch and wait’ management and this was
particularly true for those with normal serum immunoglobulin levels.
Relatively few patients in our cohort were in remission from
previous chemotherapy but it appears that antibody responses in
this group are also more robust and this would be compatible
with previously published work [13]. Other limitations of our work
include patient self-reporting for infection history and previous
COVID-19 infection, a lack of nucleocapsid-specific antibody
assessment in the DBS samples, inability to link to current
haematological parameters, and the relatively small number of
samples after the second vaccine as a result of the extended
interval programme.
Our findings raise questions regarding optimal vaccination policy
for patients with CLL and the potential need for additional
management. The great majority of the UK population is receiving
the Covid-19 vaccine with an ‘extended interval’ of 10–12 weeks
between doses. As such, in this interim report the majority of
samples were obtained after the first vaccine but before the second
dose and suggest that patients with CLL should be considered for
early delivery of the second vaccine. However, antibody responses
may remain suboptimal even after two vaccines. One option might
be to consider a third ‘booster’ vaccine and this is being
implemented in some countries for patients in other risk groups.
At this stage it is not clear if a third vaccine will indeed act to further
boost antibody responses although the substantial increment after
the second boost and the high antibody titres observed following
natural infection suggest that this may be possible. It is possible that
vaccination may serve to provide sufficient ‘immune-priming’ to
protect against severe disease from subsequent infection even in the
absence of a measurable spike-specific antibody response. Indeed,
we have not yet assessed the profile of spike-specific cellular
immunity following vaccination and, although cellular immune
responses are also typically suboptimal in patients with CLL, these
are likely to provide some protection from severe disease [24].
However, antibody levels are emerging as a correlate of immune
protection [20, 25] and as such the administration of prophylactic
SARS-CoV-2-specific antibodies to patients at the greatest clinical risk
could be valuable.
In conclusion we show that antibody responses following
Covid-19 vaccination are reduced in patients with CLL, with
patients who are IgA-deficient or on BTKi therapy at particular risk
for failure to develop a response. It is now critical that the clinical
efficacy of vaccination is determined in this patient group using
data linkage from large population datasets and this assessment is
underway in many countries. This information, together with
assessment of immune correlates, will be important to guide the
ongoing requirement for behavioural adjustments such as social
distancing.
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